117 related articles for article (PubMed ID: 38100920)
21. Different pathologic types of early stage lung adenocarcinoma have different post-operative recurrence patterns.
Liu X; Sun K; Yang F; Sui X; Jiang G; Wang J; Li X
Thorac Cancer; 2021 Aug; 12(15):2205-2213. PubMed ID: 34180578
[TBL] [Abstract][Full Text] [Related]
22. High-grade tumor classified by new system is a prognostic predictor in resected lung adenocarcinoma.
Yoshida C; Yokomise H; Ibuki E; Go T; Haba R; Kadota K
Gen Thorac Cardiovasc Surg; 2022 May; 70(5):455-462. PubMed ID: 35050467
[TBL] [Abstract][Full Text] [Related]
23. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
Wu C; Rao X; Lin W
Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of mutant p53, Ki-67, and TTF-1 and their correlation with EGFR mutation in patients with non-small cell lung cancer.
Zhu WY; Hu XF; Fang KX; Kong QQ; Cui R; Li HF; He JY; Zhang YK; Le HB
Histol Histopathol; 2019 Nov; 34(11):1269-1278. PubMed ID: 31062864
[TBL] [Abstract][Full Text] [Related]
25. Association of thyroid transcription factor-1 with the efficacy of immune-checkpoint inhibitors in patients with advanced lung adenocarcinoma.
Nakahama K; Kaneda H; Osawa M; Izumi M; Yoshimoto N; Sugimoto A; Nagamine H; Ogawa K; Matsumoto Y; Sawa K; Tani Y; Mitsuoka S; Watanabe T; Asai K; Kawaguchi T
Thorac Cancer; 2022 Aug; 13(16):2309-2317. PubMed ID: 35808895
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical study of thyroid transcription factor-1 and HER2/neu in non-small cell lung cancer: strong thyroid transcription factor-1 expression predicts better survival.
Haque AK; Syed S; Lele SM; Freeman DH; Adegboyega PA
Appl Immunohistochem Mol Morphol; 2002 Jun; 10(2):103-9. PubMed ID: 12051626
[TBL] [Abstract][Full Text] [Related]
27. Thyroid transcription factor-1 expression is an independent predictor of recurrence and correlates with the IASLC/ATS/ERS histologic classification in patients with stage I lung adenocarcinoma.
Kadota K; Nitadori J; Sarkaria IS; Sima CS; Jia X; Yoshizawa A; Rusch VW; Travis WD; Adusumilli PS
Cancer; 2013 Mar; 119(5):931-8. PubMed ID: 23096929
[TBL] [Abstract][Full Text] [Related]
28. Elevated FAM83A expression predicts poorer clincal outcome in lung adenocarcinoma.
Zhang J; Sun G; Mei X
Cancer Biomark; 2019; 26(3):367-373. PubMed ID: 31594212
[TBL] [Abstract][Full Text] [Related]
29. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.
Wang W; Ren S; Wang Z; Zhang C; Huang J
Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070
[TBL] [Abstract][Full Text] [Related]
30. [Correlation of caveolin-1 expression with clinicopathologic features and prognosis in patients with lung adenocarcinoma].
Wang Y; Liu B; Xu Y; Zhang J; Xia Q; Yu B; Zhang R; Shi S; Lu Z; Zhou X
Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):251-5. PubMed ID: 24915816
[TBL] [Abstract][Full Text] [Related]
31. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
Wu P; Zheng Y; Wang Y; Wang Y; Liang N
J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
[TBL] [Abstract][Full Text] [Related]
32. Optimised architecture-based grading system as an independent prognostic factor in resected lung adenocarcinoma.
Qiu JH; Hu GM; Zhang RZ; Hu M; Li Z; Zhang Y; Wu HF; Fu WJ; Zhang M; Feng YK; Niu L; Ren JL
J Clin Pathol; 2022 Mar; 75(3):176-184. PubMed ID: 33372106
[TBL] [Abstract][Full Text] [Related]
33. Prognostic relevance of TTF-1 and MMP-9 expression in advanced lung adenocarcinoma.
Martins SJ; Takagaki TY; Silva AG; Gallo CP; Silva FB; Capelozzi VL
Lung Cancer; 2009 Apr; 64(1):105-9. PubMed ID: 18801593
[TBL] [Abstract][Full Text] [Related]
34. [Value of thyroid transcription factor-1 in identification of the prognosis of bronchioloalveolar carcinoma].
Wang CL; Yue DS; Zhang ZF; Zhan ZL; Sun LN
Zhonghua Yi Xue Za Zhi; 2007 Sep; 87(33):2350-4. PubMed ID: 18036300
[TBL] [Abstract][Full Text] [Related]
35. Pathological high malignant grade is higher risk of recurrence in pN0M0 invasive lung adenocarcinoma, even with small invasive size.
Ito M; Miyata Y; Kushitani K; Kagimoto A; Ueda D; Tsutani Y; Takeshima Y; Okada M
Thorac Cancer; 2021 Dec; 12(23):3141-3149. PubMed ID: 34643053
[TBL] [Abstract][Full Text] [Related]
36. Identification of a methylomics-associated nomogram for predicting overall survival of stage I-II lung adenocarcinoma.
Wang H; Wei C; Pan P; Yuan F; Cheng J
Sci Rep; 2021 May; 11(1):9938. PubMed ID: 33976305
[TBL] [Abstract][Full Text] [Related]
37. Diagnosis of lymph node micrometastasis at the pN₀ stage of lung adenocarcinoma using a combination of markers.
Liu H; Ye YK; Li GM; Zhou Y; Han KB; Xu G; Wang D
Genet Mol Res; 2014 Jul; 13(3):5594-600. PubMed ID: 25117316
[TBL] [Abstract][Full Text] [Related]
38. High grade tumor budding is associated with poor survival in pathologic stage I lung adenocarcinoma.
Gürçay N; Acar LN; Ünal TDK; Tanrıkulu FB; Biner İU; Bulut S; Baykal H; Demirağ F; Fındık G
Ann Diagn Pathol; 2023 Oct; 66():152188. PubMed ID: 37566939
[TBL] [Abstract][Full Text] [Related]
39. Podoplanin expression in cancer-associated fibroblasts predicts unfavourable prognosis in patients with pathological stage IA lung adenocarcinoma.
Kubouchi Y; Yurugi Y; Wakahara M; Sakabe T; Haruki T; Nosaka K; Miwa K; Araki K; Taniguchi Y; Shiomi T; Nakamura H; Umekita Y
Histopathology; 2018 Feb; 72(3):490-499. PubMed ID: 28881047
[TBL] [Abstract][Full Text] [Related]
40. TYK2 is a prognostic biomarker and associated with immune infiltration in the lung adenocarcinoma microenvironment.
He A; Zhang R; Wang J; Huang Z; Liao W; Li Y; Wang C; Yang J; Feng Q; Wu L
Asia Pac J Clin Oncol; 2022 Apr; 18(2):e129-e140. PubMed ID: 33852776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
